Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis

Cancer Gene Therapy

Volumn 14, Issue 7, 2007, Pages 616-626

  Ek, E T H ^a   Dass, C R ^a,b   Contreras, K G ^a   Choong, P F M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Angiogenesis; Antitumor; Metastasis; Osteosarcoma; PEDF

Indexed keywords

COLLAGEN TYPE 1; MATRIGEL; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMID DNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOTOPIC TRANSPLANTATION; OSTEOSARCOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANIMALS; BONE NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DNA, COMPLEMENTARY; EYE PROTEINS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; MICROCIRCULATION; MUSCLE, SKELETAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; OSTEOSARCOMA; RATS; RNA; SERPINS; TRANSFECTION;

RATTUS;

EID: 34250352217     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701044     Document Type: Article

References (38)

1. Campanacci M. Bone Tumors. 2nd edn. Lippincott-Verlag: Austria, 1999.
2. Huvos A. Bone tumors: Diagnosis, Treatment and Prognosis. 2nd edn. WB Saimders: Philadelphia, PA, 1991.
3. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
4. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32: 423-436.
5. Voute PA, Souhami RL, Nooij M, Somers R, Cortes-Funes H, van der Eijken JW et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European osteosarcoma intergroup (EOI). Ann Oncol 1999; 10: 1211-1218.
6. Harris MB, Gieser P, Goorin AM, Ayala A, Shochat SJ, Ferguson WS et al. Treatment of metastatic osteosarcoma at diagnosis: a pediatric oncology group study. J Clin Oncol 1998; 16: 3641-3648.
7. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 1989; 30: 1700-1707.
8. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-414.
9. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
10. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006; 12: 497-502.
11. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006; 12: 3510-3517.
12. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int J Mol Med 2006; 17: 937-944.
13. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004; 64: 5664-5671.
14. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64: 3533-3537.
15. Guan M, Yam HF, Su B, Chan KP, Pang CP, Liu WW et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003; 56: 277-282.
16. Sidle DM, Maddalozzo J, Meier JD, Cornwell M, Stellmach V, Crawford SE. Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. Arch Otolaryngol Head Neck Surg 2005; 131: 990-995.
17. Ek ET, Dass CR, Choong PF. Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther 2006; 5: 1641-1646.
18. Hase R, Miyamoto M, Uehara H, Kadoya M, Ebihara Y, Murakami Y et al. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin Cancer Res 2005; 11: 8737-8744.
19. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9: 774-780.
20. Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004; 164: 1225-1232.
21. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001; 114: 4421-4428.
22. Cheung LW, Au SC, Cheung AN, Ngan HY, Tombran-Tink J, Auersperg N et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 2006; 147: 4179-4191.
23. Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 2001; 7: 1654-1660.
24. Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 2006; 23: 367-380.
25. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474-2484.
26. Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 2002; 277: 45400-45407.
27. Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif Tissue Int 2005; 76: 146-153.
28. Quan GM, Ojaimi J, Nadesapillai AP, Zhou H, Choong PF. Resistance of epiphyseal cartilage to invasion by osteosarcoma is likely to be due to expression of antiangiogenic factors. Pathobiology 2002; 70: 361-367.
29. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 349-357.
30. Pignolo RJ, Rotenberg MO, Cristofalo VJ. Analysis of EPC-1 growth state-dependent expression, specificity, and conservation of related sequences. J Cell Physiol 1995; 162: 110-118.
31. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005; 65: 5144-5152.
32. Compagni A, Christofori G. Recent advances in research on multistage tumorigenesis. Br J Cancer 2000; 83: 1-5.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
34. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
35. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006; 281: 3604-3613.
36. Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep 2006; 16: 17-23.
37. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004; 11: 325-332.
38. Kido A, Tsutsumi M, Iki K, Takahama M, Tsujiuchi T, Morishita T et al. Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats. Cancer Lett 1999; 137: 209-216.